Literature DB >> 8985193

Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus.

S Rabatić1, A Gagro, R Lokar-Kolbas, V Krsulović-Hresić, Z Vrtar, T Popow-Kraupp, V Drazenović, G Mlinarić-Galinović.   

Abstract

Infection with respiratory syncytial virus (RSV) may induce asthma-like symptoms and RSV-specific IgE in infected infants as a result of Th2-like response to RSV. The effect of RSV infection on the expression of B cell antigens CD21 and CD23, putative participants in Th2 responses, was investigated. Samples from bronchiolitic infants (n = 19) were tested by three-color immunofluorescence flow cytometry during the acute phase of infection and 4-6 weeks later. In 6 of 10 RSV-positive infants, the percentage of CD23+ B cells was higher than in 9 RSV-negative children and in controls. Both CD21+ and CD21- B cells exhibited a higher percentage of CD23. The group with increased expression of CD23 antigen had RSV-specific IgE and IgG4 antibodies. These findings corroborate the hypothesis that RSV could provoke a Th2-type response, but the relationship between CD23 antigen and RSV infection must be determined.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985193     DOI: 10.1093/infdis/175.1.32

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Epidemiology of Infections and Development of Asthma.

Authors:  Jenny Resiliac; Mitchell H Grayson
Journal:  Immunol Allergy Clin North Am       Date:  2019-04-30       Impact factor: 3.479

3.  A hypothesis: antenatal sensitisation to respiratory syncytial virus in viral bronchiolitis.

Authors:  J P Legg; C A Jones; J A Warner; S L Johnston; J O Warner
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791

Review 4.  The immune response to respiratory syncytial virus infection: friend or foe?

Authors:  Robert C Welliver
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

5.  Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis.

Authors:  A Gagro; M Tominac; V Krsulović-Hresić; A Baće; M Matić; V Drazenović; G Mlinarić-Galinović; E Kosor; K Gotovac; I Bolanca; S Batinica; S Rabatić
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 6.  Role of viruses in the development of atopic disease in pediatric patients.

Authors:  Dorothy S Cheung; Mitchell H Grayson
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

7.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Respiratory syncytial virus infection and virus-induced inflammation are modified by contaminants of indoor air.

Authors:  Serene Foster; Kirk J Bedford; Melanie E L Gould; William R Coward; Colin R A Hewitt
Journal:  Immunology       Date:  2003-01       Impact factor: 7.397

Review 9.  Respiratory viral infections and atopic development: From possible mechanisms to advances in treatment.

Authors:  Lisa M Martorano; Mitchell H Grayson
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

Review 10.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.